Company Profile

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Latest News

Mizuho Raises Price Target on Amylyx Pharmaceuticals to $24 From $21, Keeps Outperform Rating

MT Newswires • 07/20/2026

Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight

PR Newswire • 07/07/2026

Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data?

Insider Monkey • 06/30/2026

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

Business Wire • 06/23/2026

A Look At Amylyx Pharmaceuticals (AMLX) Valuation After Its Recent Share Price Rebound

Simply Wall St. • 06/01/2026